GENERATION BIO CO (GBIO) Stock Overview
USA - NASDAQ:GBIO - US37148K2096 - Common Stock
GBIO Key Statistics, Chart & Performance
The current stock price of GBIO is 5.715 USD. In the past month the price decreased by -9.92%. In the past year, price decreased by -76.46%.
GBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.69 | 387.04B | ||
| AMGN | AMGEN INC | 12.43 | 145.98B | ||
| GILD | GILEAD SCIENCES INC | 14.33 | 137.67B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.74 | 98.78B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.25 | 59.24B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.29B | ||
| ARGX | ARGENX SE - ADR | 77.26 | 43.83B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.7 | 38.73B | ||
| INSM | INSMED INC | N/A | 28.75B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.39B | ||
| NTRA | NATERA INC | N/A | 22.07B | ||
| BIIB | BIOGEN INC | 8.56 | 20.10B |
Related stock screener links
About GBIO
Company Profile
Generation Bio Co. is a genetic medicine company, which focuses on creating a new class of gene therapy to provide durable and redosable treatment for patients suffering from both rare and prevalent diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 115 full-time employees. The company went IPO on 2020-06-12. The firm is engaged in developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. The company focuses on autoimmune targets that have been undruggable or poorly drugged selectively in T cells. Its proprietary cell-targeted lipid nanoparticle (ctLNP) technology enables selective access to T cells and precise target inhibition by siRNA to selectively modulate T cells, blocking autoimmune tissue damage while sparing the broader immune system. Its proprietary stealth technology prevents its LNP from interacting with serum-binding proteins and reduces clearance by the liver and spleen to less than 1%, enabling potency and selectivity. Its selective delivery allows it to inhibit targets in T cells while sparing critical function in other cell types.
Company Info
GENERATION BIO CO
301 Binney Street
Cambridge MASSACHUSETTS 02142 US
CEO: Geoff McDonough
Employees: 115
Phone: 18575295908
GENERATION BIO CO / GBIO FAQ
What is the stock price of GENERATION BIO CO today?
The current stock price of GBIO is 5.715 USD. The price decreased by -0.09% in the last trading session.
What is the ticker symbol for GENERATION BIO CO stock?
The exchange symbol of GENERATION BIO CO is GBIO and it is listed on the Nasdaq exchange.
On which exchange is GBIO stock listed?
GBIO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for GENERATION BIO CO stock?
12 analysts have analysed GBIO and the average price target is 27.29 USD. This implies a price increase of 377.43% is expected in the next year compared to the current price of 5.715. Check the GENERATION BIO CO stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is GENERATION BIO CO worth?
GENERATION BIO CO (GBIO) has a market capitalization of 38.52M USD. This makes GBIO a Nano Cap stock.
How many employees does GENERATION BIO CO have?
GENERATION BIO CO (GBIO) currently has 115 employees.
What are the support and resistance levels for GENERATION BIO CO (GBIO) stock?
GENERATION BIO CO (GBIO) has a support level at 5.71 and a resistance level at 5.76. Check the full technical report for a detailed analysis of GBIO support and resistance levels.
Is GENERATION BIO CO (GBIO) expected to grow?
The Revenue of GENERATION BIO CO (GBIO) is expected to decline by -41.57% in the next year. Check the estimates tab for more information on the GBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy GENERATION BIO CO (GBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of GBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of GBIO, evaluating the profitability, health, valuation and growth aspects
- GENERATION BIO CO (GBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- GENERATION BIO CO (GBIO) Sales and EPS estimates to see what analysts future expectations are.
- GENERATION BIO CO (GBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- GENERATION BIO CO (GBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- GENERATION BIO CO (GBIO) Stock Chart to make your own analysis
- GENERATION BIO CO (GBIO) Latest news and press-releases to stay up to date.
Does GENERATION BIO CO (GBIO) stock pay dividends?
GBIO does not pay a dividend.
When does GENERATION BIO CO (GBIO) report earnings?
GENERATION BIO CO (GBIO) will report earnings on 2025-11-04, after the market close.
What is the Price/Earnings (PE) ratio of GENERATION BIO CO (GBIO)?
GENERATION BIO CO (GBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.82).
What is the Short Interest ratio of GENERATION BIO CO (GBIO) stock?
The outstanding short interest for GENERATION BIO CO (GBIO) is 3.39% of its float. Check the ownership tab for more information on the GBIO short interest.
GBIO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GBIO. When comparing the yearly performance of all stocks, GBIO turns out to be only a medium performer in the overall market: it outperformed 60.45% of all stocks.
GBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to GBIO. GBIO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GBIO Financial Highlights
Over the last trailing twelve months GBIO reported a non-GAAP Earnings per Share(EPS) of -10.82. The EPS decreased by -108.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.36% | ||
| ROE | -133.86% | ||
| Debt/Equity | 0 |
GBIO Forecast & Estimates
12 analysts have analysed GBIO and the average price target is 27.29 USD. This implies a price increase of 377.43% is expected in the next year compared to the current price of 5.715.
For the next year, analysts expect an EPS growth of -20.82% and a revenue growth -41.57% for GBIO